Canadian Small caps and Penny stocks
- Last Updated:
- May 11th, 2023 8:36 am
Tags:
- SCORE+19
- mohaken
- Deal Addict
- Jun 23, 2006
- 1782 posts
- 247 upvotes
- Toronto
- badass
- Deal Addict
- Dec 24, 2007
- 1993 posts
- 513 upvotes
- Toronto
AGN is moving fast with today’s good news.
CEO and CSO are talking at lunch today, hopefully we close near .60 today.
Cheers and GLTA that are still holding.
CEO and CSO are talking at lunch today, hopefully we close near .60 today.
Cheers and GLTA that are still holding.
Thread started in 2016 - 1927 fully gutted and renovated 2 storey detached home in the big T.O. - small projects still in progress.
RFD priceless!
RFD priceless!
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
Entered VS @ .22.
LITT is halted pending news.
GSI continues to look very strong. Gapped up this morning.
EDIT: LITT was apparently halted by SEC due to their previous COVID-19 related claims. Not good.
LITT is halted pending news.
GSI continues to look very strong. Gapped up this morning.
EDIT: LITT was apparently halted by SEC due to their previous COVID-19 related claims. Not good.
Last edited by izzyzz on Apr 14th, 2020 1:27 am, edited 1 time in total.
- Ketchenany
- Deal Addict
- Jan 31, 2016
- 1008 posts
- 710 upvotes
Bought PBX @ .145. I was interested in this before this news below.
https://www.globenewswire.com/news-rele ... where.html
Update edit : .135 now
https://www.globenewswire.com/news-rele ... where.html
Update edit : .135 now
Those who dance are considered insane by those who cannot hear the music - Carlin
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
VS
Versus Partners with Kast to Expand Beyond Gaming Into Streaming Video
LOS ANGELES, April 14, 2020 (GLOBE NEWSWIRE) -- Versus Systems, Inc. ("Versus") (CSE:VS) (OTCQB:VRSSF) (FRANKFURT:BMVA) today announces an agreement with Kast to bring Versus’ proprietary in-app rewards technology to Kast’s successful watch party platform.
This is an important step for Versus in that Kast is the first non-gaming content partner to integrate the Versus rewards platform. Social streaming, watch parties and video are a part of what Business Wire estimates as a $250 Billion dollar global streaming market that is estimated to grow at 19% CAGR through 2024.
Kast is a real-time video sharing app with screen capture, voice, text, and video chat technology that makes it easy to connect with friends wherever they are in a watch party. Kast is the ultimate virtual living room solution for all your content needs. Kast has recently been featured in well-known media outlets like Wired, Mashable, The Next Web, The Evening Standard, NBC and more.
The two companies will work together to integrate real-world rewards into Kast’s watch party apps to increase engagement for hosts of watch parties, known as “Kasters,” and watch party spectators alike.
“Kast is a true pioneer in the watch party space,” said John O’Connell, Head of Business Development for Versus Systems. “We are excited to bring our in-game reward technologies to their apps, creators and spectators later this year.”
Justin Weissberg, Co-founder and President of Kast commented: “Versus brings real, tangible rewards to their partners’ growing audiences. We are excited to bring our community rewards they can experience with their Kast friends and family.”
Versus Partners with Kast to Expand Beyond Gaming Into Streaming Video
LOS ANGELES, April 14, 2020 (GLOBE NEWSWIRE) -- Versus Systems, Inc. ("Versus") (CSE:VS) (OTCQB:VRSSF) (FRANKFURT:BMVA) today announces an agreement with Kast to bring Versus’ proprietary in-app rewards technology to Kast’s successful watch party platform.
This is an important step for Versus in that Kast is the first non-gaming content partner to integrate the Versus rewards platform. Social streaming, watch parties and video are a part of what Business Wire estimates as a $250 Billion dollar global streaming market that is estimated to grow at 19% CAGR through 2024.
Kast is a real-time video sharing app with screen capture, voice, text, and video chat technology that makes it easy to connect with friends wherever they are in a watch party. Kast is the ultimate virtual living room solution for all your content needs. Kast has recently been featured in well-known media outlets like Wired, Mashable, The Next Web, The Evening Standard, NBC and more.
The two companies will work together to integrate real-world rewards into Kast’s watch party apps to increase engagement for hosts of watch parties, known as “Kasters,” and watch party spectators alike.
“Kast is a true pioneer in the watch party space,” said John O’Connell, Head of Business Development for Versus Systems. “We are excited to bring our in-game reward technologies to their apps, creators and spectators later this year.”
Justin Weissberg, Co-founder and President of Kast commented: “Versus brings real, tangible rewards to their partners’ growing audiences. We are excited to bring our community rewards they can experience with their Kast friends and family.”
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
Added more VS @ .215 at open. Idiots selling here but thank you. lol
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
Grabbed some IPA @ .84.
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
This is also interesting with regards to IPA...
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
RLV is reporting some very decent sales numbers. I bought some back @ .05 to see what happens.
Relevium Reports $250,000 in Pre-Sales for Bioganix® CleanCare Hand Sanitizers in First 6 Days
https://www.globenewswire.com/news-rele ... -Days.html
Relevium Reports $250,000 in Pre-Sales for Bioganix® CleanCare Hand Sanitizers in First 6 Days
https://www.globenewswire.com/news-rele ... -Days.html
- lilmikey
- Deal Addict
- Nov 14, 2006
- 3149 posts
- 1952 upvotes
- GTA
MWM running, saw it too late so not going to chase at this point.
- gdhundal
- Newbie
- Sep 26, 2016
- 9 posts
- 1 upvote
Thoughts on Datameterex? They're kits worked well in South Korea and they're currently in the process of getting approved by the FDA/CDC and Health Canada. Kits provide results in 15-20 minutes and are said to be 99.9% accurate.
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
I got some at .12 on pullback today.
Generally, I'd approach this one with caution and a stop loss. The company is known for promo driven sp rise, then fall. Quite diluted as well. Haven't seen this much volume on any stock in recent history though so it creates some nice opportunities if you play the volatility right.
- gdhundal
- Newbie
- Sep 26, 2016
- 9 posts
- 1 upvote
I found their revised news release from earlier this morning. I'm guessing that's why the SP dropped today. Do you think there's still a chance they get approved in North America?
http://datametrex.com/investor/pr/Datam ... Korea.html
http://datametrex.com/investor/pr/Datam ... Korea.html
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
I don't think revised NR had anything with today's drop. It went up way too fast and got extremely overbought. This type of setup always invites short sellers. Money is made both ways.
No reason to believe they can't get it approved but this is all spec driven right now because we don't know how much DM will be making from selling those kits. I do not plan on holding long-term.
No reason to believe they can't get it approved but this is all spec driven right now because we don't know how much DM will be making from selling those kits. I do not plan on holding long-term.
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
Sold DM @ .14 (.12 avg).
@jimgiggles is right. These guys are sketchy. Play accordingly.
Also sold NSP @ .035 (.03 avg). Not particularly happy about PP at current levels. Could have done better by selling earlier but decent profit.
@jimgiggles is right. These guys are sketchy. Play accordingly.
Also sold NSP @ .035 (.03 avg). Not particularly happy about PP at current levels. Could have done better by selling earlier but decent profit.
Last edited by izzyzz on Apr 20th, 2020 12:51 pm, edited 2 times in total.
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
IPA related...
COVID-19 Collaboration For Johnson & Johnson's Janssen Unit, And Other News: The Good, Bad And Ugly Of Biopharma
https://seekingalpha.com/article/433841 ... nd-ugly-of
COVID-19 Collaboration For Johnson & Johnson's Janssen Unit, And Other News: The Good, Bad And Ugly Of Biopharma
https://seekingalpha.com/article/433841 ... nd-ugly-of
- jimgiggles
- Sr. Member
- Jul 23, 2006
- 614 posts
- 93 upvotes
- Toronto
I removed earlier post about $DM.. Didn't want to get flamed with all the momentum on that stock..
Stage Zero Life Sciences out of Markham looks very promising....
$SZLS had a major news release today and it's sitting at about $.085 at the moment.. I got in at $.065 and holding tight.
https://twitter.com/stagezerols?lang=en
StageZero Life Sciences Initiates Testing for COVID-19 In the USA
T.SZLS | 4 hours ago
TORONTO, ON / ACCESSWIRE / April 20, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") announced today that it is initiating testing for the SARS-CoV-2 virus from its CLIA-certified high complexity lab in Richmond, Virginia. The Company will offer both the PCR-based nucleic acid tests as well qualitative antibody testing. Quantitative antibody testing will be added once fully validated and approved.
The Company is first directing its testing to healthcare groups and frontline workers, which will include employers of frontline workers. As capacity grows, testing will be offered to physician groups with established patient relationships.
The PCR test:
PCR tests help determine if a patient has an active infection. StageZero is using Thermo Fisher Scientific's TaqPath RT-PCR Covid-19 kit to test for the SARS-CoV-2 virus. The kit has an EUA clearance and StageZero will operate under this authorization. The Company routinely uses Thermo Fisher Scientific equipment and procedures to conduct its RT-PCR mRNA analyses for its cancer screening tests, and is completing validation of the Covid-19 assay. This will be filed with the FDA this week which will allow testing to begin.
Qualitative antibody test:
Antibody tests can aid in the diagnosis of patients with suspected SARS-CoV-2 virus infection in conjunction with clinical presentation and the results of other laboratory tests. Antibody tests help determine if a patient has already been infected with the virus and is producing antibodies. StageZero is partnered with BTNX Inc. and will offer qualitative antibody testing using BTNX's Rapid Response COVID-19 IgG/IgM Test. The assays test for the presence of IgM and IgG and have a validated specificity of 99%, the key benchmark for these tests. On March 16, 2020 BTNX submitted under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019 and is listed on the FDA site. Subsequently, they submitted the kits to the New York State Department of Health for evaluation and confirmation of their results and are presently submitting an EUA to the FDA for approval.
StageZero will initially offer the BTNX Rapid Response test under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019 while awaiting EUA approval. FDA, CLIA and CAP guidelines lay out how the testing is to be conducted at this time:
The tests must be conducted within a CLIA-certified high complexity lab.
The test must be performed on a venous blood sample collected by a certified healthcare professional.
The tests need an authorized test requisition.
The results must be reported daily to the relevant State and Federal authorities under the signature of the lab.
"This is a highly coordinated effort to deliver COVID-19 testing as correctly and accurately as possible," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "In recent weeks there have been growing backlogs of patient samples being held up for testing due to high demand and limited capacity. These partnerships will ease some of that backlog".
COVID-19 Testing for Frontline Workers
StageZero Life Sciences will initially be offering SARS-CoV-2 virus testing to employers and healthcare workers serving on the frontlines. This will be expanded to physician groups with established patient relationships as testing capacity increases. Capacity is anticipated to ramp-up fairly quickly.
Telehealth a Critical Component of Testing to Reach Employees and Patients
StageZero Life Sciences has been offering testing via its own telehealth platform for well over a year. StageZero's Telehealth Platform allows physicians to initiate an order for blood tests for prostate, colorectal or breast cancer. Once authorized, the test requisitions are sent to a lab partner or our proprietary network of mobile phlebotomists who can perform blood draws in a patient's home.
"The telehealth model which has been thrust upon the country in recent weeks is something StageZero has been preparing for for well over a year," said Howard-Tripp. "Now, because of advanced planning, we are uniquely positioned to be able to get to "socially distanced" employees and patients to offer COVID-19 testing. We are, however, first and foremost a Cancer diagnostic company and will remain focused there. For now though, we are very pleased to be able to help."
About StageZero Life Sciences, Ltd.
StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, our next generation test, is a panel for simultaneously screening for 10 discrete cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Company Contacts:
James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1
Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838
SOURCE: StageZero Life Sciences Ltd
View source version on accesswire.com:
https://www.accesswire.com/585873/Stage ... In-the-USA
ACCESSWIRE
April 20, 2020 - 5:00 AM PDT
Stage Zero Life Sciences out of Markham looks very promising....
$SZLS had a major news release today and it's sitting at about $.085 at the moment.. I got in at $.065 and holding tight.
https://twitter.com/stagezerols?lang=en
StageZero Life Sciences Initiates Testing for COVID-19 In the USA
T.SZLS | 4 hours ago
TORONTO, ON / ACCESSWIRE / April 20, 2020 / StageZero Life Sciences, Ltd (TSX:SZLS) ("StageZero" or the "Company") announced today that it is initiating testing for the SARS-CoV-2 virus from its CLIA-certified high complexity lab in Richmond, Virginia. The Company will offer both the PCR-based nucleic acid tests as well qualitative antibody testing. Quantitative antibody testing will be added once fully validated and approved.
The Company is first directing its testing to healthcare groups and frontline workers, which will include employers of frontline workers. As capacity grows, testing will be offered to physician groups with established patient relationships.
The PCR test:
PCR tests help determine if a patient has an active infection. StageZero is using Thermo Fisher Scientific's TaqPath RT-PCR Covid-19 kit to test for the SARS-CoV-2 virus. The kit has an EUA clearance and StageZero will operate under this authorization. The Company routinely uses Thermo Fisher Scientific equipment and procedures to conduct its RT-PCR mRNA analyses for its cancer screening tests, and is completing validation of the Covid-19 assay. This will be filed with the FDA this week which will allow testing to begin.
Qualitative antibody test:
Antibody tests can aid in the diagnosis of patients with suspected SARS-CoV-2 virus infection in conjunction with clinical presentation and the results of other laboratory tests. Antibody tests help determine if a patient has already been infected with the virus and is producing antibodies. StageZero is partnered with BTNX Inc. and will offer qualitative antibody testing using BTNX's Rapid Response COVID-19 IgG/IgM Test. The assays test for the presence of IgM and IgG and have a validated specificity of 99%, the key benchmark for these tests. On March 16, 2020 BTNX submitted under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019 and is listed on the FDA site. Subsequently, they submitted the kits to the New York State Department of Health for evaluation and confirmation of their results and are presently submitting an EUA to the FDA for approval.
StageZero will initially offer the BTNX Rapid Response test under Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019 while awaiting EUA approval. FDA, CLIA and CAP guidelines lay out how the testing is to be conducted at this time:
The tests must be conducted within a CLIA-certified high complexity lab.
The test must be performed on a venous blood sample collected by a certified healthcare professional.
The tests need an authorized test requisition.
The results must be reported daily to the relevant State and Federal authorities under the signature of the lab.
"This is a highly coordinated effort to deliver COVID-19 testing as correctly and accurately as possible," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "In recent weeks there have been growing backlogs of patient samples being held up for testing due to high demand and limited capacity. These partnerships will ease some of that backlog".
COVID-19 Testing for Frontline Workers
StageZero Life Sciences will initially be offering SARS-CoV-2 virus testing to employers and healthcare workers serving on the frontlines. This will be expanded to physician groups with established patient relationships as testing capacity increases. Capacity is anticipated to ramp-up fairly quickly.
Telehealth a Critical Component of Testing to Reach Employees and Patients
StageZero Life Sciences has been offering testing via its own telehealth platform for well over a year. StageZero's Telehealth Platform allows physicians to initiate an order for blood tests for prostate, colorectal or breast cancer. Once authorized, the test requisitions are sent to a lab partner or our proprietary network of mobile phlebotomists who can perform blood draws in a patient's home.
"The telehealth model which has been thrust upon the country in recent weeks is something StageZero has been preparing for for well over a year," said Howard-Tripp. "Now, because of advanced planning, we are uniquely positioned to be able to get to "socially distanced" employees and patients to offer COVID-19 testing. We are, however, first and foremost a Cancer diagnostic company and will remain focused there. For now though, we are very pleased to be able to help."
About StageZero Life Sciences, Ltd.
StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, our next generation test, is a panel for simultaneously screening for 10 discrete cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Company Contacts:
James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1
Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838
SOURCE: StageZero Life Sciences Ltd
View source version on accesswire.com:
https://www.accesswire.com/585873/Stage ... In-the-USA
ACCESSWIRE
April 20, 2020 - 5:00 AM PDT
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
Playing the old stinker GAME. Picked up some shares @ .485 at open.
Torque Esports deliver new gaming streams for major brands in #StayAtHomeEconomy
https://www.prnewswire.com/news-release ... 44385.html
Torque Esports deliver new gaming streams for major brands in #StayAtHomeEconomy
https://www.prnewswire.com/news-release ... 44385.html
- izzyzz
- Deal Fanatic
- May 2, 2006
- 8355 posts
- 2267 upvotes
- GTA
Sold DOC @ .59 (avg .45). Hitting overbought area.
Bought MBX @ .32 on news:
Microbix Biosystems : Attains Health Canada Establishment Licensing
https://www.marketscreener.com/MICROBIX ... -30452659/
Bought MBX @ .32 on news:
Microbix Biosystems : Attains Health Canada Establishment Licensing
https://www.marketscreener.com/MICROBIX ... -30452659/
Last edited by izzyzz on Apr 21st, 2020 9:00 pm, edited 1 time in total.
Thread Information
There is currently 1 user viewing this thread. (0 members and 1 guest)